The mostpromisingnewdirectionforCNS (central nervoussystem) drugdevelopment appears to be focusingontreatments that act on more thanonemoleculartarget.
Huang is now turning his focus beyond gamers to a host of new customers that will need number-crunching power: oil companies doing deep-sea seismic analysis, Wall Street banks modeling portfolio risk and biologists visualizing molecular structures to find drugtarget sites.
One possibility is that the amyloid theory is right, but that the Eli Lilly drug is flawed and did not hit the proper moleculartarget, and ended up merely causing toxicity.